Cargando…

Immune tolerance induction in patients with severe hemophilia A with inhibitors

BACKGROUND: Inhibitory antibodies to factor VIII (FVIII) are an important complication when managing patients with hemophilia A. Immune tolerance induction (ITI) has been regarded as a useful method for eradicating inhibitors. We report the results of a retrospective study in Korean patients with he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ryu, Ji Eun, Park, Young Shil, Yoo, Ki Young, Lee, Kyoo Duck, Choi, Yong-Mook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705051/ https://www.ncbi.nlm.nih.gov/pubmed/26770953 http://dx.doi.org/10.5045/br.2015.50.4.248

Ejemplares similares

The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors
por: Ju, Hee Young, et al.
Publicado: (2015)

Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center
por: Yoo, Ki Young, et al.
Publicado: (2016)

Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A
por: Schep, Sarah J., et al.
Publicado: (2021)

Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
por: Sun, Jie, et al.
Publicado: (2022)

Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia
por: Rezaieyazdi, Zahra, et al.
Publicado: (2020)

Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study
por: Kim, Soon Ki, et al.
Publicado: (2017)

Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis
por: Oomen, Ilja, et al.
Publicado: (2022)

Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience
por: Han, Myung Hee, et al.
Publicado: (2013)

Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors
por: Li, Zekun, et al.
Publicado: (2021)

Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China
por: Li, Zekun, et al.
Publicado: (2019)

Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce
por: Herzog, Roland W., et al.
Publicado: (2017)

Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab
por: Lee, Min Young, et al.
Publicado: (2023)

Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2020)

Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran
por: Rasekh, Hamid Reza, et al.
Publicado: (2011)

Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia
por: Park, Young Shil
Publicado: (2021)

Comparison of continuous infusion versus bolus injection of factor concentrates for blood management after total knee arthroplasty in patients with hemophilia
por: Park, Young Shil, et al.
Publicado: (2017)

Safety and effectiveness of Rixubis in patients with hemophilia B: a real-world, prospective, postmarketing surveillance study in South Korea
por: Choi, Eun Jin, et al.
Publicado: (2020)

Induction of liver transplant immune tolerance in an outbred rat strain model using tacrolimus
por: Park, Min-Jung, et al.
Publicado: (2023)

Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients
por: You, Chur Woo, et al.
Publicado: (2019)

Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors
por: Saba, Hussain I, et al.
Publicado: (2011)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Low‐dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success
por: Elalfy, Mohsen, et al.
Publicado: (2021)

Induction of Donor-Specific Tolerance: Is This Achievable?
por: Cho, Eun Jin, et al.
Publicado: (2012)

Induction of Oral Tolerance by Gamma-Irradiated Ovalbumin Administration
por: Yang, Hui, et al.
Publicado: (2016)

Tissue Inhibitor of Metalloproteinase-1 Enhances Eosinophilic Airway Inflammation in Severe Asthma
por: Cao, Thi Bich Tra, et al.
Publicado: (2023)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Clinical Application of Factor VIII:C to VWF:Ag Ratio for the Screening of Haemophilia A Carriers
por: Yoo, Ki-Young, et al.
Publicado: (2022)

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status
por: Batsuli, Glaivy, et al.
Publicado: (2021)

Impact of the Induction of Labor on Hemophilia Carriers and Their Newborn Infants
por: Shibahara, Mami, et al.
Publicado: (2021)

Nonfactor Therapies for Hemophilia
por: Young, Guy
Publicado: (2023)

Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays
por: Kizilocak, Hande, et al.
Publicado: (2019)

Predictors of the outcome of immune tolerance induction in patients with haemophilia A and inhibitors: The Brazilian Immune Tolerance (BrazIT) Study protocol
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2021)

Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia
por: Kim, In Jung, et al.
Publicado: (2022)

Health-related quality of life of moderate and severe haemophilia patients: Results of the haemophilia-specific quality of life index in Korea
por: Baek, Hee Jo, et al.
Publicado: (2020)

Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE)
por: Young, Guy, et al.
Publicado: (2012)

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
por: Albattat, Sami, et al.
Publicado: (2023)

Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells
por: Choi, Soon-Youn, et al.
Publicado: (2017)

Quality of Life in Hemophilia Complicated by Inhibitors
por: Bastani, P, et al.
Publicado: (2012)

Escape or Fight: Inhibitors in Hemophilia A
por: Merlin, Simone, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gla1vqnh9ok7oo51898u8g10er